Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

Phase 3 Unknown 600 enrolled West Japan Thoracic Oncology Group

RandomizedParallel-groupOpen-labelTreatment

Summary

To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.

Timeline

Start: 2001-12
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UFT	Unknown	250 mg/m2	—
Subject	gemicitabine	Unknown	1000 mg/m2	—

Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

Summary

Timeline

Drugs

Indications